We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Paul Bellamy
Paul Bellamy
Products
PRODUCTS
Novel Laboratories, Inc.
Paul Bellamy
and
Nancy M. Espinal
Price:
$117.00
View
InvaTech Pharma Solutions
Paul Bellamy
and
Nancy M. Espinal
Price:
$117.00
View
Village Pharmacy
Paul Bellamy
and
Nancy M. Espinal
Price:
$117.00
View
Mycone Dental Supply Co., Inc. Dba Keystone Industries
Paul Bellamy
Price:
$117.00
View
Cetylite Industries, Inc.
Paul Bellamy
and
Nancy M. Espinal
Price:
$117.00
View
SaveWay Compounding Pharmacy, Inc.
Paul Bellamy
Price:
$117.00
View
Amneal Pharmaceuticals, LLC
Paul Bellamy
Price:
$117.00
View
West-Ward Pharmaceutical Corp.
Paul Bellamy
,
Stephen Mottola
, and
Lauren L. Vajo
Price:
$117.00
View
CMIC CMO USA Corp.
Paul Bellamy
,
Rose Xu
, and
Ying Zhang
Price:
$117.00
View
Tris Pharma, Inc.
Paul Bellamy
Price:
$117.00
View
View All Products by Paul Bellamy
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
